Deal volumes for global pharmaceutical mergers and acquisitions were lower in 2023 than they were 10 years ago. They’ve also been lower, on average, than the four years prior to the highs in 2018 and 2019. There were some encouraging signs as the industry (and especially large drugmakers) headed into 2024, including a rise in average premiums in the pharma industry, yet 2024’s numbers year to date point to a down year for these types of deals. Since 2019, deal volumes have broken the $200 billion mark only once, in 2023. Last year’s $215.9 billion annual deal volume also represented the greatest year-over-year increase (2022 had $178.2 billion in deal volume) since the jump from 2017 to 2018.
Read the full article: Pharma M&A Deals Reveal Down Decade, Uncertain Future //
Source: https://news.bloomberglaw.com/bloomberg-law-analysis/analysis-pharma-m-a-deals-reveal-down-decade-uncertain-future